The AP1 transcription factor Batf3 is required for homeostatic development of CD8a 1 classical dendritic cells that prime CD8 T-cell responses against intracellular pathogens. Here we identify an alternative, Batf3-independent pathway in mice for CD8a 1 dendritic cell development operating during infection with intracellular pathogens and mediated by the cytokines interleukin (IL)-12 and interferon-c. This alternative pathway results from molecular compensation for Batf3 provided by the related AP1 factors Batf, which also functions in Tand B cells, and Batf2 induced by cytokines in response to infection. Reciprocally, physiological compensation between Batf and Batf3 also occurs in T cells for expression of IL-10 and CTLA4. Compensation among BATF factors is based on the shared capacity of their leucine zipper domains to interact with non-AP1 factors such as IRF4 and IRF8 to mediate cooperative gene activation. Conceivably, manipulating this alternative pathway of dendritic cell development could be of value in augmenting immune responses to vaccines.
The AP1 transcription factor Batf3 is required for homeostatic development of CD8a 1 classical dendritic cells that prime CD8 T-cell responses against intracellular pathogens. Here we identify an alternative, Batf3-independent pathway in mice for CD8a 1 dendritic cell development operating during infection with intracellular pathogens and mediated by the cytokines interleukin (IL)-12 and interferon-c. This alternative pathway results from molecular compensation for Batf3 provided by the related AP1 factors Batf, which also functions in Tand B cells, and Batf2 induced by cytokines in response to infection. Reciprocally, physiological compensation between Batf and Batf3 also occurs in T cells for expression of IL-10 and CTLA4. Compensation among BATF factors is based on the shared capacity of their leucine zipper domains to interact with non-AP1 factors such as IRF4 and IRF8 to mediate cooperative gene activation. Conceivably, manipulating this alternative pathway of dendritic cell development could be of value in augmenting immune responses to vaccines. BATF 1 and BATF3 are activator protein 1 (AP1) 2 transcription factors 3, 4 with immune-specific functions [5] [6] [7] [8] . Batf is required for development of T-helper cells producing IL-17 (T H 17) and follicular helper T (T FH ) cells 5 , and class-switch recombination (CSR) in B cells 6, 9 . Batf3 is required for development of CD8a 1 classical dendritic cells (cDCs) and related CD103 1 dendritic cells 8 that cross-present antigens to CD8 T cells 7 and produce IL-12 in response to pathogens 10 .
We recently recognized a heterozygous phenotype for Batf3 of 50% fewer CX3CR1 2 CD8a 1 cDCs in Batf3 1/2 mice 11 , indicating that levels of BATF3 are limiting for CD8a 1 dendritic cell development under homeostatic conditions. While analysing Toxoplasma gondii infection in Batf3 2/2 mice, we observed evidence indicating Batf3independent CD8a 1 cDC development 10 based on apparent priming of pathogen-specific CD8 T cells in Batf3 2/2 mice treated with IL-12.
Here we report a Batf3-independent pathway of CD8a 1 cDC development that functions physiologically during infection by intracellular pathogens and describe its molecular basis, which involves compensatory BATF factors.
Pathogens and IL-12 restore CD8a 1 cDCs in Batf3 2/2 mice IL-12 administration to Batf3 2/2 mice before infection with type II Prugniaud (Pru) T. gondii reversed their susceptibility by inducing interferon (IFN)-c production not only from natural killer (NK) cells but also from CD8 T cells 10 , indicating potentially restored crosspriming. To test this idea, we infected Batf3 2/2 mice with the attenuated 12 RHDku80Drop5 strain of T. gondii and examined CD8a 1 cDCs ( Supplementary Fig. 1a ). Notably, CD8a 1 cDCs reappeared in spleens of Batf3 2/2 mice by day 10 after infection. Infection by Listeria monocytogenes also restored CD8a 1 cDC production in Batf3 2/2 mice ( Supplementary Fig. 1b ). Aerosol-mediated infection with Mycobacterium tuberculosis caused a progressive restoration of CD8a 1 cDCs in Batf3 2/2 mice and expanded CD8a 1 cDCs in wild-type mice (Fig. 1a) . Mycobacterium tuberculosis infection of Batf3 2/2 mice restored the missing lung-resident CD103 1 cDCs (DEC205 1 CD24 1 CD4 2 SIRP-a 2 CD11b 2 ) 8, 13 ( Supplementary Fig. 1c ). Batf3 2/2 mice showed no difference in survival to M. tuberculosis infection compared to wild-type mice ( Supplementary Fig. 1d ), suggesting that the initial lack of CD8a 1 cDCs and peripheral CD103 1 cDCs was not sufficient for lethality with M. tuberculosis. Because IL-12 is important in control of M. tuberculosis 14 , we measured serum IL-12 levels in M. tuberculosis-infected wild-type and Batf3 2/2 mice (Fig. 1b ). IL-12 levels were reduced in Batf3 2/2 mice in the first 3 weeks, but increased after 6 weeks to approximately 50% of M. tuberculosis-infected wild-type mice.
We found that IL-12 administration restored CD8a 1 cDC production in all backgrounds of Batf3 2/2 mice ( Fig. 1c and Supplementary Fig. 2a ). Restored CD8a 1 cDCs were functional for cross-presentation 7, 15, 16 ( Fig. 2a and Supplementary Fig. 2b ). Purified splenic CD8a 1 and CD4 1 cDCs from wild-type or Batf3 2/2 mice, treated with vehicle or IL-12, were tested for cross-presentation. As a control, OT-I T cells proliferated in response to wild-type CD8a 1 dendritic cells, but not CD4 1 dendritic cells, co-cultured with ovalbumin-loaded cells with or without IL-12 treatment ( Fig. 2a ). Importantly, OT-I T cells proliferated similarly in response to IL-12-induced Batf3 2/2 CD8a 1 dendritic cells, but not Batf3 2/2 CD4 1 dendritic cells, as to wild-type CD8a 1 cDCs. The CD8a 1 cDCs restored by IL-12 administration in Batf3 2/2 mice showed a gene expression profile that was more similar to wild-type CD8a 1 dendritic cells than to CD4 1 cDCs ( Supplementary Fig. 2c ). A total of 1,855 genes differed more than fourfold in expression between IL-12-induced CD8a 1 cDCs and CD4 1 cDCs within Batf3 2/2 mice. However, in comparing IL-12-induced CD8a 1 cDCs in Batf3 2/2 mice with the rare CD8a 1 cDCs from Batf3 2/2 C57BL/6 mice, or with CD8a 1 cDCs in wild-type mice, there were only 34 and 206 genes, respectively, differing more than fourfold in expression.
The IL-12-induced restoration of CD8a 1 cDCs in Batf3 2/2 mice was dependent on IFN-c in vivo ( Supplementary Fig. 2d ). With administration of control antibody, IL-12 induced a threefold increase in CD8a 1 cDCs in wild-type mice and restored CD8a 1 cDC production in Batf3 2/2 mice. Both effects were blocked by anti-IFN-c antibody. IL-12 induced IFN-c production from NK cells but not T cells ( Supplementary Fig. 2e ), and IL-12 treatment was able to restore CD8a 1 cDCs in Rag2 2/2 Batf3 2/2 mice ( Supplementary Fig. 2f ), indicating that T cells and B cells are not required for this effect.
Batf3 2/2 mice fail to reject highly immunogenic H31m1 and D42m1 fibrosarcomas 7 . However, Batf3 2/2 mice pre-treated with IL-12 either fully rejected or showed reduced growth of these fibrosarcomas ( Fig. 2b and Supplementary Fig. 2g ). Rejection was not simply due to NK cell activation, as IL-12 treatment failed to alter tumour growth in Rag2 2/2 mice. Notably, IL-12-treated Batf3 2/2 mice re-established priming of CD8 T cells capable of infiltrating tumours similar to wild-type mice ( Fig. 2c ). Mice with the inactivating IRF8 R249C mutation [17] [18] [19] failed to restore CD8a 1 cDCs upon IL-12 administration ( Supplementary  Fig. 3a ), indicating that restoration requires functional IRF8 protein. Furthermore, these mice were highly susceptible to infection by aerosoladministered M. tuberculosis 20 ( Supplementary Fig. 3b ), indicating that Batf3 2/2 mice may resist M. tuberculosis infection by restoration of CD8a 1 cDCs. Thus, physiological Batf3-independent development of CD8a 1 cDCs is induced by pathogens, mediated by IL-12 and IFN-c.
Batf, Batf2 and Batf3 cross-compensate
We next investigated whether Batf could replace Batf3 for in vitro cDC development 7, 21 (Fig. 3a ). CD103 1 SIRP-a 2 cDCs do not develop in Flt3L-treated Batf3 2/2 bone marrow cultures. Retroviral expression of Batf3 into Batf3 2/2 bone marrow progenitors restored CD103 1 cDC development. Notably, Batf expression fully and cell-intrinsically restored CD103 1 SIRP-a 2 cDC development, whereas Fos was inactive ( Supplementary Fig. 3c ). CD103 1 cDCs restored by Batf and Batf3 expression in vitro were functional, showing features of mature CD103 1 cDCs, including loss of SIRP-a and CD11b expression, upregulation of CD24, and selective production of IL-12 in response to T. gondii antigen ( Supplementary Fig. 3c, d ). Reciprocally, Batf3 but not Fos restored cell-intrinsic IL-17a production by Batf 2/2 T cells and CSR in Batf 2/2 B cells ( Supplementary Fig. 3e , f). Thus, Batf and Batf3 can molecularly cross-compensate for several distinct lineage-specific functions, activities not shared by Fos.
We also identified in vivo compensation between Batf and Batf3 in dendritic cells. On the 129SvEv and BALB/c backgrounds, Batf3 2/2 mice completely lack CD8a 1 cDCs ( Fig. 3b and Supplementary Fig. 2a ). In contrast, C57BL/6 Batf3 2/2 mice retain a 3-7% population of CD8a 1 cDCs 19, 22 in spleen and unexpectedly retain a completely normal population of CD8a 1 cDCs in skin-draining inguinal lymph nodes (ILNs) (Fig. 3b ). These CD8a 1 cDCs are functional, as C57BL/6 Batf3 2/2 mice showed robust priming of CD8 T cells against herpes simplex virus (HSV) infection in the footpad, whereas 129SvEv Batf3 2/2 mice, lacking CD8a 1 cDCs in ILNs, did not ( Supplementary Fig. 3g ). However, C57BL/6 Batf 2/2 Batf3 2/2 mice lack CD8a 1 dendritic cells in ILNs and fail to prime T cells against HSV. Thus, retention of functional CD8a 1 cDCs in ILNs of C57BL/6 Batf3 2/2 mice is Batf-dependent.
Batf and Batf3 also compensate in expression of genes by T cells. IL-4 and IL-10 production was not substantially affected in either Batf 2/2 or Batf3 2/2 T H 2 cells ( Fig. 3c and Supplementary Fig. 3i -k). However, IL-10 is reduced at least eightfold in Batf 2/2 Batf3 2/2 T H 2 Fig. 1c , dendritic cells were purified by sorting as CD3 2 DX5 2 MHCII 1 CD11c 1 SIRP-a 2 CD24 1 DEC205 1 dendritic cells (CD8DC) and CD3 2 DX5 2 MHCII 1 CD11c 1 SIRPa 1 CD24 2 DEC205 2 dendritic cells (CD4DC) and assayed for crosspresentation 7 . OT-I proliferation in response to cDCs mixed with the indicated number of MHC-class-I-deficient ovalbumin (Ova)-loaded splenocytes is shown. b, Wild-type or Batf3 2/2 mice treated with vehicle (PBS) or with IL-12 were inoculated with 1 3 10 6 H31m1 fibrosarcomas. Tumour size in individual mice is shown. c, Mice in b were analysed by FACS 11 days after H31m1 inoculation for CD8 T-cell infiltration into tumours 7 . 
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cells. Also, expression of the inhibitory receptor CTLA4 is partially reduced in Batf 2/2 T H 2 cells but reduced threefold further in Batf 2/2 Batf3 2/2 T H 2 cells. In contrast, IFN-c production by T H 1 cells is unaffected by loss of Batf, Batf3 or both. We asked whether IL-12-induced restoration of CD8a 1 cDCs in Batf3 2/2 mice was due to compensation by Batf ( Supplementary  Fig. 3h ). Restoration of splenic CD8a 1 cDCs in IL-12-treated Batf 2/2 Batf3 2/2 mice was reduced to 5% from 11% in IL-12-treated Batf3 2/2 mice. Whereas Batf seems to be responsible for roughly half of the IL-12-induced restoration of CD8a 1 cDCs in Batf3 2/2 mice, some residual compensation remained in Batf 2/2 Batf3 2/2 mice. We asked if a third factor might compensate for Batf and Batf3. Batf2 (also called SARI) 23 is closely related to Batf and Batf3 and is induced by lipopolysaccharide (LPS) and IFN-c in macrophages and CD103 1 dendritic cell populations ( Supplementary Fig. 4a -c). We found that Batf2 was induced by IFN-c in wild-type and Batf3 2/2 dendritic cells derived from Flt3L-cultured bone marrow ( Supplementary Fig. 4d , e) and in vivo by IL-12 in dendritic cells in Batf3 2/2 mice (Supplementary Fig. 4f ). Induction of Batf2 by IFN-c in cDCs made it a potential candidate to mediate IFN-c-dependent compensation for Batf3.
We generated Batf2 2/2 mice by targeting exons 1 and 2, eliminating BATF2 protein expression ( Supplementary Fig. 5 ). Batf2 2/2 mice had normal development of NK, T and B cells, pDCs, neutrophils, resting cDCs, and peritoneal, liver and lung macrophages (Supplementary Fig. 6a -c). However, Batf2 2/2 mice displayed significantly decreased survival after infection by T. gondii (Pru) ( Fig. 4a ), although parasite burden and serum cytokine levels were similar to wild-type mice ( Supplementary Fig. 7a, b ). Notably, Batf2 2/2 mice showed significantly decreased numbers of lung-resident CD103 1 CD11b 2 dendritic cells and CD103 2 CD11b 2 macrophages after infection ( Fig. 4b and Supplementary Fig. 7c ). These changes were specific, as there were no differences in other myeloid subsets ( Supplementary Fig. 7d, e ). Thus, Batf2 has a role in maintaining numbers of Batf3-dependent CD103 1 dendritic cells in the lung after infection with T. gondii.
We next investigated whether Batf2 could compensate for dendritic cell defects in Batf3 2/2 mice and for T and B cell defects in Batf 2/2 mice ( Fig. 4c and Supplementary Fig. 8a, b ). Like Batf, retroviral expression of Batf2 restored development of CD103 1 SIRP-a 2 dendritic cells in Flt3L-treated Batf3 2/2 bone marrow. Unlike Batf and Batf3, expression of Batf2 did not restore T H 17 development in Batf 2/2 T cells and only weakly restored CSR in Batf 2/2 B cells. Thus, Batf2 selectively compensates for Batf and Batf3 in cDCs but not in T or B cells. We next mice. a, Wild-type or Batf3 2/2 bone marrow cells were infected with GFP-RV 35 (empty) or retrovirus expressing the indicated cDNA and cultured with Flt3L 7 . Histograms for the indicated markers are for B220 2 CD11c 1 cells on day 10. Numbers are the per cent of cells in the gate. b, Inguinal lymph nodes from wild-type, Batf3 2/2 or Batf 2/2 Batf3 2/2 mice on 129SvEv or C57BL/6 backgrounds were analysed by FACS. Shown are histograms for DEC205 and CD8a. c, CD4 T cells of the indicated genotype were differentiated twice under T H 2 conditions 5 and analysed by FACS for intracellular IL-10.
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examined in vivo IL-12-induced restoration of CD8a 1 cDCs in Batf2 2/2 , Batf3 2/2 and Batf2 2/2 Batf3 2/2 mice ( Fig. 4d and Supplementary Fig. 8c ). IL-12 treatment restored CD8a 1 cDCs from ,1% to .5% of total cDCs in Batf3 2/2 mice, but this was significantly reduced to ,2% in Batf2 2/2 Batf3 2/2 mice. This suggests that Batf2 is responsible for roughly half of IL-12-induced CD8a 1 cDC restoration in Batf3 2/2 mice. We found similar results with in vitro CD103 1 cDC development. Whereas granulocyte-macrophage colony-stimulating factor (GM-CSF) restored only CD103 and not DEC205 expression in Flt3L-treated Batf3 2/2 bone marrow cultures 19 , adding IFN-c with GM-CSF restored DEC205 1 CD103 1 CD11b 2 dendritic cells (Supplementary Fig. 8d, e ). We used this system to analyse compensation between Batf, Batf2 and Batf3 ( Supplementary Fig. 8d, e ). Relative to wild-type bone marrow, CD103 1 DEC205 1 CD11b 2 cDCs were partially reduced in Batf 2/2 , Batf2 2/2 and Batf3 2/2 singly deficient bone marrow, but were reduced to an even greater extent in both Batf 2/2 Batf3 2/2 and Batf2 2/2 Batf3 2/2 bone marrow relative to all single-deficient bone marrow cultures. Collectively, these results suggest that Batf and Batf2 both act in the cytokine-dependent rescue of CD8a 1 cDC development in Batf3 2/2 mice.
The BATF LZ domain interacts with IRF4 and IRF8
To understand BATF cross-compensation, we analysed chimaeric proteins containing fused domains of BATF, BATF2 and FOS ( Supplementary Fig. 9 ). FOS inactivity could result from inhibitory actions of amino-and carboxy-terminal domains missing in BATF and BATF3 ( Fig. 5a ). However, removing these domains from FOS (D59FOSD39) or fusing the BATF DNA-binding domain (DBD) with the FOS leucine zipper (LZ) (BBRFFD39) failed to restore CD103 1 cDC development ( Fig. 5a ), T H 17 development or CSR activity ( Supplementary Fig. 10a, b ). However, fusing the BATF LZ with the FOS DBD (D59FFQBB) fully restored CD103 1 cDC development in Ftl3L-treated Batf3 2/2 bone marrow cultures, fully restored CSR in Batf 2/2 B cells and exhibited 20% of wild-type activity for restoring IL-17 production. Furthermore, BATF with a C-terminal GFP (BATF-GFP) or FOS (BBBF) domain had .40% of wild-type BATF activity in all three assays ( Supplementary Fig. 11 ). Thus, the LZ domain, not the DBD, determines BATF specificity.
Removing the BATF2 C-terminal domain (BATF2 DM) allowed for full restoration of CD103 1 cDC development, but led to only partial restoration of CSR activity (,15%), and no restoration of T H 17 development ( Supplementary Fig. 10c-h antibodies c, 293FT cells expressing IRF4 (1) and the indicated BATF chimaera were analysed by EMSA with the AICE1 probe. d, B cells were analysed by EMSA with the indicated probe and competitor oligonucleotides (comp). e, Batf3 2/2 bone marrow cells infected with the indicated BATF retroviruses encoding BATF were analysed as in a. f, 293FT cells expressing the indicated BATF mutants were analysed by EMSA with the AICE1 probe.
ARTICLE RESEARCH
A recent study 24 proposed that IRF4 and BATF may interact. Correspondence between the phenotypes of Batf 2/2 with Irf4 2/2 mice, lacking T H 17 development and CSR, and Batf3 2/2 with Irf8 2/2 mice, lacking CD8a 1 cDC development ( Supplementary  Fig. 12 ) [5] [6] [7] [25] [26] [27] [28] , suggested that BATF and BATF3 may cooperate with both IRF4 and IRF8. Furthermore, ChIP-seq analysis of BATF and IRF4 revealed coincident binding to composite AP1 and IRF motifs 29, 30 . By analogy with the ETS-IRF composite elements (EICE) 31 , the AP1-IRF composite elements are designated as AICE 29, 30 . Recalling the FOS LZ interaction with NF-AT that mediates cooperative binding to Il2 regulatory regions 32 , we therefore asked whether the BATF LZ interacted with non-AP1 factors, including IRF4.
Electrophoretic mobility shift assays (EMSAs) demonstrated interactions between BATF and both IRF4 and IRF8 ( Fig. 5 and Supplementary Figs 13 and 14) . The BATF-JUN complex that formed on an AP1 consensus probe 1,2 was unchanged by addition of IRF4 or IRF8. Its abundance was increased by additional JUNB (Supplementary Fig. 13a ). However, using an AICE from the Ctla4 locus, a slower mobility complex formed with addition of either Irf4 or Irf8, which required the IRF consensus element ( Fig. 5b and Supplementary  Fig. 13b ). This BATF-JUN-IRF4 complex required both BATF and IRF protein, and IRF4 was unable to bind the AICE1 probe without BATF (Fig. 5b) . In contrast, IRF4 was able to bind to an ETS-IRF consensus element 33 (EICE) in the presence of PU.1 independently of BATF (Fig. 5b) . The BATF-JUN-IRF4 complex had similar mobility to the FOS-JUN complex in activated cells, but could be distinguished by antibody supershifts ( Supplementary Fig. 13c ). Spatial constraints on the BATF-IRF4 interaction are suggested by lack of BATF-IRF4 complex formation on the AICE2 probe with reversed orientation of the AP1 and IRF elements ( Supplementary Fig. 13a, c) .
The ability of chimaeric BATF proteins to interact with IRF4 correlated with their functional activity (Fig. 5c ). The active D59FFQBB interacted with IRF4, but the inactive D59FOSD39 and BBRFFD39 did not (Fig. 5c ), although all three bound an AP1 consensus ( Supplementary Fig. 13d ). A BATF-IRF complex also formed in B and T cells, requiring both the IRF and AP1 consensus elements ( Fig. 5d and Supplementary Fig. 14c ), and involved contribution by endogenous IRF4 and IRF8 ( Supplementary Fig. 14a, b, d) . The BATF-IRF complex was completely absent in Batf 2/2 B cells, but was partially retained in single-deficient Irf4 2/2 or Irf8 2/2 B cell extracts ( Supplementary Fig. 14a, b ). Supershifts using anti-IRF4 and anti-IRF8 antibodies in Irf4 2/2 or Irf8 2/2 B cell nuclear extracts showed that the endogenous BATF-IRF complex is composed of a mixture of IRF4 and IRF8 ( Supplementary Fig. 14b ). Similarly, supershifts of primary T H 17 cells demonstrate an interaction between BATF and both IRF4 and IRF8 ( Supplementary Fig. 14d ).
We identified BATF LZ mutations which abrogated both function and IRF4 interactions (Fig. 5e, f) . Positions b, c and f of the FOS LZ face away from the parallel coiled-coil of the JUN LZ and mediate interactions with NF-AT 32 (Supplementary Fig. 9d ). Several BATF mutations in these positions had no effect on activity (Supplementary Table 1 and Supplementary Fig. 9c ). However, four residues together controlled nearly all BATF-specific activity ( Fig. 5e and Supplementary 15 ). BATF(L56A), BATF(K63D) and BATF(E77K) showed no reduction in CD103 1 cDC development, and retained .60% of wild-type BATF activity in CSR. In contrast, BATF(H55Q) activity was reduced by nearly 70% (Fig. 5e ). Double mutants BATF(K63D/E77K) and BATF(H55Q/L56A) were reduced by 50% and 75%, but quadruple mutant BATF(H55Q/L56A/K63D/E77K) had less than 10% of wild-type BATF activity in CD103 1 cDC development (Fig. 5e ). This loss of activity was specific, as two other quadruple mutants-BATF(E59Q/D60Q/K63D/E77K) and BATF(K63D/R69Q/ K70D/E77K)-maintained .50% of wild-type BATF activity ( Supplementary Fig. 15c, d) . A similar pattern was seen for CSR in Batf 2/2 B cells ( Supplementary Fig. 15b ). The activity of these mutants correlated with IRF4 interaction (Fig. 5f ). Wild-type BATF and functional mutant BATF(K63D/E77K), and both functional quadruple mutants, formed a complex with IRF4, whereas the less active BATF(H55Q) and BATF(H55Q/L56A), and the completely inactive BATF(H55Q/L56A/K63D/E77K), did not, although all were stably expressed and could bind an AP1 site (Supplementary 13e, f).
Discussion
We have uncovered a cytokine-driven pathway for expansion of functional CD8a 1 cDCs occurring physiologically during infection by intracellular pathogens. This pathway relies on functional compensation for Batf3 provided by Batf and Batf2 through a shared specificity defined by the BATF LZ domain to support CD8a 1 cDC and T H 17 development, and CSR in B cells. This compensatory pathway of CD8a 1 cDC development may provide a basis for augmenting therapeutic immune responses. The basis of this shared specificity is the LZ interaction with non-AP1 factors, including IRF4 and IRF8, extending the repertoire of AP1 interactions beyond the recognized association of FOS with NF-AT 32 . The ability of both BATF and BATF3 to support both IRF4-and IRF8-dependent lineage activities implies that the specificity for gene activation is determined largely by the IRF factors. An important next step will be to determine how regulatory elements discriminate between these distinct complexes.
METHODS SUMMARY
Mice. Batf 2/2 , Batf2 2/2 and Batf3 2/2 mice and intercrosses were bred in our specific pathogen-free animal facility according to institutional guidelines. Irf8 2/2 mice from the European Mutant Mouse Archive and BXH2/TyJ mice from The Jackson Laboratory were maintained on the C57BL/6 background. Germline-deleted Irf4 2/2 mice were produced from crossing B6.129S1-Irf4 tm1Rdf /J mice obtained from The Jackson Laboratory with a CMV-Cre deleter strain on the C57BL/6 background. Experiments were in accordance with procedures approved by the AAALAC accredited Animal Studies Committee of Washington University in St Louis. In vivo IL-12 treatment. Recombinant murine IL-12 (Peprotech and Pfizer) was suspended in pyrogen-free saline at 2.5 mg ml 21 . Mice were injected intraperitoneally with 0.5 mg of IL-12 two times 3 days before analysis. For tumour transplantation and tumour collection experiments, mice were treated on days 4, 3 and 1 before tumour inoculation and 24 h after tumour inoculation. thank the ImmGen consortium 34 
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Generation of Batf2 2/2 mice. The targeting construct was assembled by Gateway recombination cloning system (Invitrogen). To construct pENTR loxFRT rNEO, a floxed PGK-neo r (phosphoglycerate kinase promoter-neomycin phosphotransferase) gene cassette (1,982 bp) was excised from the pLNTK targeting vector 36 using SalI and XhoI. After incubation with Easy-A cloning enzyme (Stratagene) and dNTPs to generate 39-A overhangs, the PGK-neo r cassette was ligated into the multiple cloning site of pGEM-T Easy (Promega). The resulting 2,022-bp PGK-neo r gene cassette was released using NotI and ligated into the 2,554-bp backbone of NotI-digested pENTR lox-Puro 37 . Flippase Recognition Target (FRT) sites were sequentially inserted at the SacI and HindIII sites using DNA fragments generated by following annealing oligonucleotides: SacII-FRT-A (59-GAAGTTCCTATTCCGAAGTTCCTATTC TCTAGAAAGTATAGGAACTTCCGC-39) and SacII-FRT-B (59-GGAAGT TCCTATACTTTCTAGAGAATAGGAACTTCGGAATAGGAACTTCGC-39), or HindIII-FRT-A (59-AGCTTGAAGTTCCTATTCCGAAGTTCCTATTCTC TAGAAAGTATAGGAACTTC-39) and HindIII-FRT-B (59-AGCTGAAGTTC CTATACTTTCTAGAGAATAGGAACTTCGGAATAGGAACTTCA-39).
To construct pENTR-BATF2-5HA, the 59 homology arm was generated by PCR from genomic DNA using the following oligonucleotides, which contain the attB4 and attB1r site: 59-GGGGACAACTTTGTATAGAAAAGTTGGCAGGCT GAAGCAGGGACAC-39, and 59-GGGGACTGCTTTTTTGTACAAACTTGC CCTAGCACACCCAGTTTCAGTTTC-39. The attB4-attB1r PCR fragment was ligated into pDONR(P4-P1R) plasmid (Invitrogen) by BP recombination reaction. To construct pENTR-BATF2-3HA, the 39 homology arm was generated by PCR from genomic DNA using the following oligonucleotides which contain attB2 and attB3site: 59-GGGGACAGCTTTCTTGTACAAAGTGGGCAGTCC CAGCATGACCCAGCCCCAGCATGACCCAGCATCTGC-39, and 59-GGGG ACAACTTTGTATAATAAAGTTGCCGTCTCACTCAGTTCTGTGTGTG-39. The attB2-attB3 PCR fragment was ligated into pDONR(P2-P3) plasmid (Invitrogen) by BP recombination reaction, following by the LR recombination reaction to generate final targeting construct by using pENTR-BATF2-5HA, pENTR-BATF2-3HA, pENTR-loxFRT rNEO, and pDEST DTA-MLS. The linearized vector was electroporated into EDJ22 embryonic stem cells, on the 129 SvEv background, and targeted clones were identified by Southern blot analysis with 59 and 39 probes. Blastocyst injections were performed, and male chimaeras were bred to female 129S6/SvEv mice. Probes for Southern blot analysis were amplified from genomic DNA using the following primers: 59-GTTGGTGTGAGGTGATGAGGTCCC-39 and 59-CTTGACTTCCTAGAC CAGGGGC-39 for the 59 probe; 59-GGACCATATACTCTTACTGTTGAAA CC-39 and 59-GGGCTGGGGACACACATG-39 for the 39 probe. Southern blot analysis and genotyping PCR were performed to confirm germline transmission and the genotype of the progeny. Primers used for genotyping PCR are shown as follows: knockout screen forward, 59-GAAACTGAAACTGGGTGTGCTA GGG-39; knockout screen reverse, 59-CGCCTTCTTGACGAGTTCTTCTG AG-39; wild-type screen reverse, 59-GCCTTCCTTGTCTCTCTCCATAGCG-39. Generation of BATF2-specific rabbit polyclonal antibody. Murine full-length Batf2 cDNA was cloned into the pET-28a (1) expression vector (Novagen) to generate recombinant BATF2 protein with a His tag. Recombinant BATF2 was then expressed using Escherichia coli BL21 (Invitrogen). Purified recombinant BATF2 was used to immunize New Zealand white rabbits (Harlan), and rabbit anti-mouse BATF2 sera were collected and tested by ELISA and western blot analysis. Pathogen infections. Listeria monocytogenes and T. gondii infections were carried out as previously described 38, 39 . The type II avirulent Prugniaud (Pru) strain of T. gondii expressing a firefly luciferase and GFP transgene (provided by J. Boothroyd) was used for infections of Batf2 2/2 mice for the experiments shown in Fig. 4 and Supplementary Fig. 7 . Briefly, 800 tachyzoites were injected intraperitoneally (i.p.) into mice. For herpes simplex virus 1 (HSV-1) infections, mice were infected with the KOS strain subcutaneously (s.c.) with 1.5 3 10 5 plaque-forming units (p.f.u.) per mouse in the footpad. Viral supernatant and HSV peptide were provided by M. Colonna. For M. tuberculosis infections, Erdman strain was grown to a density of 8 3 10 6 colony-forming units (c.f.u.) per ml, and mice were exposed to aerosol infection for 40 min using a Glas-Col aerosol exposure system. After 24 h, two mice per group were killed, and lungs were collected to determine infection efficiency, which was about 100 c.f.u. per lung. Lungs and spleens were collected at 1, 3 and 9 weeks after infection. The left lobe of the lung and one-third of the spleen were used for histological examination upon formalin fixation. The right lobe of the lung and two-thirds of the spleen were divided into c.f.u. analysis and FACS analysis. For c.f.u. analysis, organs were homogenized and plated at various dilutions on 7H-10 culture plates, and after 3 weeks, colonies were counted. For FACS analysis, organs were prepared as described 40 . For lungs, Ficoll gradient purification was performed before surface staining. All samples were fixed upon staining for 20 min in 4% formalin. Serum was collected by retro-orbital bleeding at week 1, 2, 3 and 6 and decontaminated by double filtering through a 0.2-mm filter. Bioluminescence imaging. Imaging was done as previously described 41 . In brief, mice were injected intraperitoneally with D-luciferin (Biosynth AG) at 150 mg kg 21 and allowed to remain active for 5 min before being anaesthetized with 2% isoflurane for 5 min. Animals were than imaged with a Xenogen IVIS200 machine (Caliper Life Sciences). Data were analysed with the Living Image software (Caliper Life Sciences).
In vitro T-cell re-stimulation after HSV infection. One week after infection, spleens were collected and re-stimulated with the HSV peptide HSV-gB2 (498-505) (Anaspec). Briefly, 2 3 10 6 splenocytes were re-stimulated for 5 h in the presence of brefeldin A at 1 mg ml 21 and analysed by FACS for intracellular IFN-c and TNF-a production as described later. In vitro cross-presentation. Dendritic cell cross-presentation of antigen to CD8 1 OT-I T cells was assessed as previously described 42 . Briefly, spleens from naive, vehicle or IL-12-treated wild-type or Batf3 2/2 mice were digested with collagenase B (Roche) and DNase I (Sigma-Aldrich). CD11c 1 dendritic cells were obtained by negative selection using B220, Thy1.2, and DX5 microbeads followed by positive selection with CD11c microbeads by MACS purification (Miltenyi Biotec). CD8a 1 and CD4 1 cDCs were cell sorted on a FACSAria II flow cytometer (post-sort purity .96%). Splenocytes from K b2/2 D b2/2 b 2 m 2/2 mice were prepared in serum-free medium, loaded with 10 mg ml 21 ovalbumin (EMD) by osmotic shock, and irradiated (13.5 Gy) as described previously 42 . OT-I T cells were purified from OT-I/Rag2 2/2 mice by CD11c and DX5 negative selection, followed by positive selection with CD8a microbeads (purity .96%). T cells were fluorescently labelled by incubation with 1 mM CFSE (Sigma-Aldrich) for 9 min at 25 uC at a density of 2 3 10 7 cells ml 21 . For the cross-presentation assay, 5 3 10 4 -10 5 purified dendritic cells were incubated with 5 3 10 4 -10 5 CFSE-labelled OT-I T cells in the presence of increasing numbers of irradiated, ovalbumin-loaded K b2/2 D b2/2 b 2 m 2/2 splenocytes (5 3 10 3 to 1 3 10 5 ). After 3 days, OT-I T cell proliferation was analysed by CSFE dilution gating on CD3 1 CD8 1 CD45.1 1 cells. Tumour transplantation. Methylcolanthrine-induced fibrosarcomas were derived from 129SvEv strain Rag2 2/2 or wild-type mice as described previously 43 . Tumour cells were propagated in vitro and 10 6 tumour cells (129SvEv fibrosarcoma tumour line H31m1 or D42m1) were injected s.c. in a volume of 150 ml endotoxin-free PBS into the shaved flanks of naive or IL-12-conditioned (as described above) wild-type Batf3 2/2 and Rag2 2/2 recipient mice as described previously 42 . Injected cells were .90% viable as assessed by trypan blue exclusion. Tumour size was measured on the indicated days and is presented as the mean of two perpendicular diameters. Tumour harvest. Wild-type and naive or IL-12-treated Batf3 2/2 mice were inoculated with the H31m1 fibrosarcoma tumour line. Eleven days after, tumours were removed, minced and treated with 1 mg ml 21 type A collagenase (Sigma) in HBSS (Hyclone) for 1 h at 37 uC. Cell suspension was analysed by FACS for CD8 T-cell recruitment at the tumour site gating on CD45 1 , Thy1.2 1 and CD8a 1 cells. Quantitative RT-PCR. For gene expression analysis, RNA was prepared from various cell types with either RNeasy Mini kit (Qiagen) or RNeasy Micro kit (QIAGEN), and cDNA was synthesized with Superscript III reverse transcription (Invitrogen). Real-time PCR and a StepOnePlus real-time PCR system (Applied Biosystems) were used according to the manufacturer's instructions, with the Quantitation Standard-Curve method and HotStart-IT SYBR Green qPCR Master Mix (Affymetrix/USB). PCR conditions were 10 min at 95 uC, followed by 40 two-step cycles consisting of 15 s at 95 uC and 1 min at 60 uC. Primers used for measurement of Batf2 expression are as follows: Batf2 qRT forward, 59-GGCAGAAGCACACCAGTAAGG-39; Batf2 qRT reverse, 59-GAAGGGC GTGGTTCTGTTTC-39. Hprt was used as normalization control, and primers used are as follows: Hprt forward, 59-TCAGTCAACGGGGGACATAAA-39; Hprt reverse, 59-GGGGCTGTACTGCTTAACCAG-39. Dendritic cell preparation. Dendritic cells from lymphoid organs and nonlymphoid organs were collected and prepared as described 40 . Briefly, spleens, MLNs, SLNs (inguinal) and liver were minced and digested in 5 ml Iscove's modified Dulbecco's media plus 10% FCS (cIMDM) with 250 mg ml 21 collagenase B (Roche) and 30 U ml 21 DNase I (Sigma-Aldrich) for 30 min at 37 uC with stirring. Cells were passed through a 70-mm strainer before red blood cells were lysed with ACK lysis buffer. Cells were counted on a Vi-CELL analyser, and 5-10 3 10 6 cells were used per antibody staining reaction. Lung cell suspensions were prepared after perfusion with 10 ml Dulbecco's PBS (DPBS) via injections into the right ventricle after transection of the lower aorta. Dissected and minced lungs were digested in 5 ml cIMDM with 4 mg ml 21 collagenase D (Roche) for 1 h RESEARCH ARTICLE at 37 uC with stirring. Cells from the peritoneal cavity were collected by washing the peritoneal cavity with 10 ml HBSS plus 2% FCS and 2 mM EDTA. Bone-marrow-derived dendritic cells and macrophages. Bone-marrow-derived dendritic cells were generated from bone marrow with 100 ng ml 21 of recombinant Flt3L as described 42 . Bone-marrow-derived macrophages were generated from bone marrow with 20 ng ml 21 of recombinant M-CSF (Peprotech) for 7 days, and rested in cIMDM without M-CSF for 24 h before stimulation with various conditions as described in the figure legends. Preparation of T. gondii lysate antigen (STAg). Toxoplasma gondii antigen was prepared by lysing tachyzoites of the Pru strain in foreskin fibroblast cultures through two cycles of freeze-thaw in liquid nitrogen. Lysate was then filtered, aliquoted at a concentration of 1 mg ml 21 in PBS and stored at 280 uC. For dendritic cell stimulation, 0.05 mg ml 21 were used and intracellular IL-12 production was analysed by FACS. Cytokine-induced CD8a 1 dendritic cells. Wild-type and Batf3 2/2 mice bone marrow was prepared as described above. GM-CSF (10 ng ml 21 ) and or IFN-c (0.1 ng ml 21 ) was added to the cultures between days 8 and 10. Cells were analysed 2 days after cytokine addition. Antibodies and flow cytometry. Staining was performed at 4 uC in the presence of Fc block (anti-CD16/32 clone 2.4G2, BioXCell) in FACS buffer (DPBS plus 0.5% BSA plus 2 mm EDTA). The antibodies used for dendritic cell analysis were as recently described 44 . Cells were analysed on BD FACSCanto II or FACSAria II and analysed with FlowJo software (Tree star, Inc.). Intracellular cytokine staining. For intracellular cytokine staining, cells were surface stained, then fixed in 2% paraformaldehyde for 15 min at 4 uC, permeabilized in DPBS plus 0.1% BSA plus 0.5% saponin, and stained for intracellular cytokines as previously described 45 . Additional antibodies included anti-TNF-a (MP6-XT22) and anti-IFN-c (XMG1.2) from BioLegend. ELISA and CBA. IL-12p40 concentration was measured from serum samples with the mouse IL-12p40 OptEIA ELISA set (BD Bioscience) according to the manufacturer's instructions. The concentration of inflammatory cytokines was measured in the serum with the BD CBA mouse inflammation kit (BD Biosciences), and data were analysed with FCAP Array software (Soft Flow, Inc.). Statistical analysis. Differences between groups in survival were analysed by the log-rank test. Analysis of all other data was done with an unpaired, two-tailed Student's t-test with a 95% confidence interval (Prism; GraphPad Software, Inc.). P values less than 0.05 were considered significant. *0.01 , P , 0.05; **0.001 , P , 0.01; ***P , 0.001; ****P , 0.0001. Expression microarray analysis. Total RNA was isolated from cells using the Ambion RNAqueous-Micro kit. For mouse genome 430 2.0 arrays, RNA was amplified, labelled, fragmented, and hybridized using the 39 IVT Express kit (Affymetrix). Data were normalized and expression values were modelled using DNA-Chip analyser (dChip) software (http://www.dChip.org) 46 . For mouse gene 1.0 ST arrays, RNA was amplified with the WT expression kit (Ambion) and labelled, fragmented and hybridized with the WT terminal labelling and hybridization kit (Affymetrix). Data were processed using RMA quantile normalization and expression values were modelled using ArrayStar software (DNASTAR). All original microarray data have been deposited in NCBI's Gene Expression Omnibus under accession number GSE40647. CD4 1 T-cell cultures. CD4 1 T cells were purified using the DynaBeads FlowComp mouse CD4 kit (Invitrogen) and were activated on anti-CD3/anti-CD28 coated plates under the following culture conditions: T H 1 conditions: anti-IL-4 10 mg ml 21 (11B11, BioXcell) , IFN-c 0.1 mg ml 21 (Peprotech), IL-12 10 U ml 21 , IL-2 40 U ml 21 ; T H 2 conditions: anti-IL-12 10 mg ml 21 (Tosh, BioXCell), anti-IFN-c 10 mg ml 21 (XMG1.2, BioXCell), IL-4 10 ng ml 21 (Peprotech), IL-2 40 U ml 21 ; T H 17 conditions: IL-6 25 ng ml 21 (Peprotech), TGF-b 2 ng ml 21 (Peprotech), IL-1b 10 ng ml 21 (Peprotech), anti-IL-4 10 mg ml 21 (11B11, BioXCell), anti-IFN-c 10 mg ml 21 (XMG1.2, BioXCell), and anti-IL-12 10 mg ml 21 (Tosh, BioXCell). IL-2 (40 U ml 21 ) was added for the T H 17 cultures in Supplementary Fig. 12a . Cells were diluted three-fold in fresh media on day 3. On day 5, cells were activated with PMA/ionomycin for analysis of cytokines and surface markers by FACS. For some experiments, cells were re-stimulated on day 7 under the same conditions and analysed 5 days later. Retroviral analysis of BATF functional activity. For CD8a 1 dendritic cell development, bone marrow was cultured with Flt3L as described 42 , infected with retrovirus and 2 mg ml 21 polybrene on day 1, and analysed for development of cDCs (CD11c 1 B220 2 ) on day 10.
CD4 1 T cells were cultured under T H 17 conditions 45, 47 and infected with retrovirus and 6 mg ml 21 polybrene on day 1. Cells were analysed on day 5 for cytokine expression by intracellular staining. For some experiments, cells were re-stimulated on day 7 under the same conditions and analysed 5 days later.
For analysis of class switch recombination, B220 cells purified by aB220 MACS microbeads (Miltenyi) were cultured with LPS and IL-4 as described 48 , infected with retrovirus and 6 mg ml 21 polybrene on day 1, and analysed for switching to IgG 1 on day 4 by FACS.
For infection of primary mouse cells, GFP-RV 49 containing cDNAs for transcription factors, chimaeric proteins and mutated BATF were transfected into Phoenix E cells as described previously 50 . Viral supernatants were collected 2 days later and concentrated by centrifugation 51 . Cells were infected with viral supernatants by spin infection at 1,800 r.p.m. for 45 min at room temperature. Electromobility shift assays (EMSAs). For stable expression in 293FT cells, retroviruses (GFP-RV containing BATF, chimaeric proteins or BATF mutants, and/or truncated hCD4-RV 49 containing IRF4 or IRF8 cDNA) were packaged in Phoenix A cells and concentrated by centrifugation 51 . Infected 293FT cells were sorted for retroviral marker expression and when indicated were transiently transfected with JUNB-GFP-RV using calcium phosphate. For transient expression, 293FT cells were transfected with retroviral constructs using calcium phosphate. Nuclear extracts were prepared 48 h after transfection. For 293FT cells, nuclei were obtained after cellular lysis with buffer A containing 0.2% NP40 and nuclear extracts in buffer C were dialysed against buffer D as described 52 . Nuclear extracts from T and B cells were prepared as described 48 .
EMSA was as described 53 using 3 mg of nuclear extract, 1 mg poly(dIdC) (Sigma) and 7%T 3.3%C polyacrylamide gels. For competition assays, extracts were incubated with excess unlabelled competitor DNA for 20 min before addition of labelled probe. For supershifts, extracts were incubated with antibodies goat anti-FOS (4) (Santa Cruz) for 293FT cells, or anti-FOS (2G9C3) (Abcam) for mouse T cells, anti-IRF4 (H-140) (Santa Cruz), anti-ICSBP (C-19) (Santa Cruz), anti-JUNB (C-11) (Santa Cruz) and rabbit anti-BATF 45 , rabbit anti-BATF2 (described above) and rabbit anti-BATF3 (W. KC et al., manuscript submitted) for 1 h on ice before addition of labelled probe and incubation at room temperature for 35 min.
The following pairs of oligonucleotides were annealed to generate probes which were labelled with 32 P-dCTP using Klenow polymerase. The AP1consensus binding site is underlined; the IRF consensus binding site is in bold; mutated bases are in lower case.
